Latest Biotech News

Alumis reported positive top-line results from two Phase 3 trials (Onward1 and Onward2) of envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints for skin clearance in...

Bright Minds Biosciences announced positive Phase 2 seizure-reduction data for its selective serotonin receptor agonist candidate, reporting statistically significant reductions across two seizure...

Moderna submitted regulatory applications in the U.S., Europe, Canada and Australia seeking approval for its mRNA seasonal flu vaccine candidate mRNA‑1010, targeted initially to people aged 50 and...

A U.S. Court of Appeals affirmed a permanent injunction that prevents the National Institutes of Health from imposing a 15% cap on indirect cost reimbursements for all grant recipients. The First...

Eli Lilly renewed a multi-year R&D partnership with Nimbus Therapeutics to pursue an oral small-molecule obesity program, agreeing to roughly $55 million in upfront and near-term payments and up...

Arrowhead Pharmaceuticals reported early-phase signals from its RNAi obesity programs, including ARO‑INHBE dosed in combination with Lilly’s tirzepatide (Zepbound). Interim results indicated...

Alumis reported topline Phase 3 results for envudeucitinib, a selective oral TYK2 inhibitor, showing statistically significant skin‑clearance outcomes in two pivotal ONWARD trials for...

Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million to add a preclinical small-molecule degrader targeting MLLT1/3 and related programs aimed at acute myeloid leukemia (AML)....

Sanofi expanded its collaboration with AI-driven biologics developer Earendil Labs to discover and develop bispecific antibodies for autoimmune and inflammatory diseases. The agreement carries...

Federal health officials revised the U.S. childhood immunization schedule, reducing routine universal recommendations from 17 diseases to 11. The change—announced under HHS direction—moves...

The U.S. Court of Appeals for the First Circuit upheld a permanent injunction preventing the National Institutes of Health from imposing a 15% across‑the‑board cap on indirect (overhead) costs for...

Bright Minds Biosciences announced positive Phase 2 results for its selective serotonin receptor agonist BMB‑101, showing clinically meaningful seizure reductions across two seizure types. The...

AI drug discovery momentum continued with an $888 million R&D collaboration between Insilico Medicine and Servier to identify oncology candidates, and publication of PEGASUS by AI biotech 1910, an...

Illumina launched Connected Multiomics, a cloud‑based software platform that integrates sequencing, AI analytics and workflows to accelerate multiomic studies for customers, positioning the...

Federal health officials moved this week to reduce the number of vaccines the U.S. routinely recommends for children, cutting the schedule from 17 to 11. The change, announced by HHS and...

Amgen agreed to acquire Oxford spinout Dark Blue Therapeutics for up to $840 million to add a preclinical small-molecule program that degrades MLLT1/3 proteins implicated in certain acute myeloid...

Eli Lilly expanded its metabolic pipeline by partnering again with AI-powered Nimbus Therapeutics on a small-molecule program aimed at treating obesity and related cardiometabolic disorders. Lilly...

Alumis reported that envudeucitinib, its selective oral TYK2 inhibitor, met primary and key secondary endpoints in two Phase 3 psoriasis trials and said it will seek regulatory approval later this...

Arrowhead Pharmaceuticals released interim Phase 1/2 data showing its RNAi candidate ARO-INHBE, given with Lilly’s tirzepatide (Zepbound), produced larger reductions in weight, visceral fat and...

Moderna submitted regulatory applications for mRNA‑1010, its mRNA‑based seasonal influenza vaccine, seeking approval for use in people 50 and older across the U.S., Europe, Canada and Australia....